Acromegaly patients face persistent symptoms including fatigue, joint pain, headaches, and brain fog despite biochemical control. Treatment burden and financial barriers remain significant, particularly in sub-Saharan Africa where diagnostic tools and therapies are often inaccessible.
A first-in-human trial shows individualized neoantigen mRNA vaccines generated multi-year T cell responses in early-stage TNBC patients, with 82.9% of targeted mutations eliciting measurable immune activation not detectable before vaccination.
Merck KGaA has entered a partnership with Calla Lily Clinical Care to advance Callavid, an intravaginal drug delivery platform designed to address patient challenges in women's health therapeutics, with initial focus on fertility and pregnancy applications.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07620067 |
GnRH for Luteal Support - Mechanism of Action |
RECRUITING | |
| NCT07608562 |
Azithromycin for Cerclage Prophylaxis |
NOT_YET_RECRUITING | PHASE4 |
| NCT06851754 |
Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency |
RECRUITING | PHASE3 |
| NCT05128071 |
PRevention Of Methamphetamine Use Among Postpartum Women Trial (PROMPT) |
COMPLETED | EARLY_PHASE1 |
